Clinical Trials Logo

Healthy Adult Participants clinical trials

View clinical trials related to Healthy Adult Participants.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06342713 Recruiting - Healthy Volunteers Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035

Start date: June 3, 2024
Phase: Phase 1
Study type: Interventional

This study is the first-in-human (FIH) study for BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different dose levels in healthy participants. Study details include: - The study duration will be up to 16 months. - The treatment duration will be up to 14 days. - Safety follow-up 30 days after last dose of study drug.

NCT ID: NCT06278389 Recruiting - Clinical trials for Healthy Adult Participants

Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

Start date: January 24, 2024
Phase: Phase 1
Study type: Interventional

The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions: - Recommended dosage for ACC017 tablets used in phase Ib/IIa trial; - The pharmacokinetic (PK) characteristics of single dose ACC017 tablets; - The effect of food (FE) on the PK of ACC017 tablets; - Drug-drug interactions (DDIs) when ACC017 tablets are co-administered with emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) tablets (II).

NCT ID: NCT06208488 Recruiting - Clinical trials for Healthy Adult Participants

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Start date: November 22, 2023
Phase: Phase 1
Study type: Interventional

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and device performance of gefurulimab.